Percutaneous treatment of saphenous vein grafts

Cardiology International

Volumn 9, Issue 2, 2008, Pages 45-50

  Agostoni, Pierfrancesco ^a   Vermeersch, P ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TACROLIMUS; ZOTAROLIMUS;

ARTIFICIAL EMBOLISM; CLINICAL TRIAL; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTECTIVE EQUIPMENT; RESTENOSIS; REVIEW; SAPHENOUS VEIN GRAFT; VEIN GRAFT DISEASE;

EID: 43249128620     PISSN: 14688581     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Fitzgibbon G, Kafka H, Leach A, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-626.
2. Alexander JH, Hafley G, Harrington RA, et al.; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-2454.
3. Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J 2007; 28: 1057-1065.
4. Weintraub WS, Jones EL, Morris DC, King SB 3rd, Guyton RA, Craver JM. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 1997; 95: 868-877.
5. Salomon N, Page U, Bigelow J, et al. Reoperative coronary surgery: comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J Thorac Cardiovasc Surg 1990; 100: 250-259.
6. Baim D. Percutaneous treatment of saphenous vein graft disease the ongoing challenge. J Am Coll Cardiol 2003; 42: 1370-1372.
7. De Feyter P, Van Suylen R, De Jaegere P, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21: 1539-1549.
8. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
9. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
10. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995; 26: 704-712.
11. Savage M, Douglas J, Fischman D, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997; 337: 740-747.
12. Hanekamp C, Koolen J, Den Heijer P, et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the VENESTENT study. Cathet Cardiovasc Interv 2003; 60: 452-457.
13. Biondi-Zoccai GG, Agostoni P, Abbate A. Parallel hierarchy of scientific studies in cardiovascular medicine. Ital Heart J 2003; 4: 819-820.
14. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 2005; 26: 804-847.
15. Webb J, Carere R, Virmani R, et al. Retrieval and analysis of particulate debris following saphenous vein graft intervention. J Am Coll Cardiol 1999; 34: 461-467.
16. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994; 9: 641-649.
17. Depre C, Havaux X, Wijns W. Pathology of restenosis in saphenous bypass grafts after long term implantation. Am J Clin Pathol 1998; 110: 378-384.
18. Van Beusekom H, Van Der Giessen W, Van Suylen R, et al. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993; 21: 45-54.
19. Farb A, Sangiorgi G, Carter A et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
20. Baldus S, Koster R, Elsner M, et al. Treatment of aortocoronary vein graft lesions with membrane-covered stents: A multicenter surveillance trial. Circulation 2000; 102: 2024-2027.
21. Schachinger V, Hamm CW, Munzel T, et al. Investigators. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003; 42: 1360-1369.
22. Stankovic G, Colombo A, Presbitero P, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003; 108: 37-42.
23. Turco MA, Buchbinder M, Popma JJ, et al. Pivotal, randomized U.S. study of the Symbiot covered stent system in patients with saphenous vein graft disease: Eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 2006; 68: 379-388.
24. Stone G, Goldberg S, Mehran R, et al. A prospective, randomized U.S. trial of the PTFE-covered JOSTENT for the treatment of diseased saphenous vein grafts: the BARRICADE trial (abstr.). J Am Coll Cardiol 2005; 45 suppl. A: 27A.
25. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105: 1285-1290.
26. Wu CJ, Yang CH, Fang CY, et al. Six-month angiographic results of primary angioplasty with adjunctive PercuSurge GuardWire device support: evaluation of the restenotic rate of the target lesion and the fate of the distal balloon occlusion site. Catheter Cardiovasc Interv 2005; 64: 35-42.
27. Agostoni P, Vermeersch P, Vydt T, et al. Acute and mid-term local vascular effects of compliant balloon inflation (GuardWire system)on saphenous vein bypass grafts: an angiographic analysis. Int J Cardiol 2007; 120: 227-231.
28. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003; 108: 548-553.
29. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007; 50: 1442-1449.
30. Mehta SK, Frutkin AD, Milford-Beland S, et al; American College of Cardiology-National Cardiovascular Data Registry. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 2007; 100: 1114-1118.
31. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106: 3063-3067.
32. Moses J, Leon M, Popma J et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Eng J Med 2003; 349: 1315-1323.
33. Stone GW, Ellis SG, Cox DA, et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
34. Fajadet J, Wijns W, Laarman GJ, et al.; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
35. Brunner-La Rocca HP, Kaiser C, Pfisterer M; BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28: 719-725.
36. Agostoni P, Vermeersch P, Verheye S, et al. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28: 1912-1913.
37. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts: 6-month angiographic, intravascular ultrasound and clinical follow up of the RRISC trial. J Am Coll Cardiol 2006; 48: 2423-2431.
38. Agostoni P, Vermeersch P, Semeraro O, et al. Intravascular ultrasound assessment of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent] trial). Am J Cardiol 2007; 100: 52-58.
39. Iakovou I, Dangas G, Mintz GS, et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol 2004; 93: 963-968.
40. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
41. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
42. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056-1061.
43. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007; 50: 261-267.
44. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
45. Hoffmann R, Hamm C, Nienaber CA, et al. Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis 2007; 18: 559-564.
46. Price M, Sawhney N, Madrid A, et al. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005; 65: 208-211.
47. Hoye A, Lemos PA, Arampatzis CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004; 16: 230-233.
48. Pucelikova T, Mehran R, Kirtane AJ, et al. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol 2008; 101: 63-68.
49. Tsuchida K, Ong AT, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005; 96: 395-398.
50. Ruchin PE, Faddy SC, Muller DW, et al. Clinical follow-up of paclitaxel-eluting (TAXUS) stents for the treatment of saphenous vein graft disease. J Interv Cardiol 2007; 20: 258-264
51. Ge L, Iakovou I, Sangiorgi G, et al. Treatment of saphenous vein graft lesions with drug eluting stents. J Am Coll Cardiol 2005; 45: 989-994.
52. Hoffmann R, Pohl T, Koster R, et al. Implantation of paclitaxel eluting stents in saphenous vein grafts: Clinical and angiographic follow-up results from a multicentre study. Heart 2007; 93: 331-334.
53. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005; 66: 507-511.
54. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-37.
55. Wohrle J, Nusser T, Kestler HA, et al. Comparison of the slow release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007; 96: 70-76.
56. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007; 19: 404-409.
57. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: results from the REAL (REgistro Regionale AngiopLastiche Emilia-Romagna) Registry. Am J Cardiol 2008; 101: 947-952.
58. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007; 20: 458-465.
59. Bansal D, Muppidi R, Singla S, et al. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 2008; 71: 58-61.
60. Chu WW, Kuchulakanti PK, Wang B, et al. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006; 19: 121-125.